MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2007

Nov 6, 2007

INVESTOR PRESENTATION

John Riemelmoser

CEO

November 2007

A company focused on developing and marketing a unique range of Safety Products led by its flagship – SecureTouch™ retractable safety syringe

Founded in 2001 by CEO, John Riemelmoser and listed on ASX in November 2005

Two acquisitions completed in early 2007:

• ProControl Systems in February 2007

• Bagot Press in May 2007

Mission

SafetyMed aims to be a global medical and health products developer, manufacturer and distributor, initially through commercialisation of its retractable syringe

Safety Medical Products Group

SafetyMed

• Development and commercialisation of innovative medical products

• Production & sales of SecureTouch™ retractable safety syringe commenced

• Direct sales for AU & NZ

• Agreement with Exelint of USA for international sales

Bagot Press

• Leading provider of printing and consumables to pharmacies

• Customer base of >2,000 pharmacies

• FY08 revenue projected to be $3.0–3.5m

• Selling SecureTouch™ & other SafetyMed products

ProControl

• Control systems and automation engineering company

• Customer base includes large & small industrial companies

• Designed & built SecureTouch™ assembly machine

• FY08 revenue projected to be $1.5– 2.0m

Highlights

• Development complete of the Company’s first full Retractable Safety Syringe, SecureTouch™.

• Australian and European Manufacturing and Sales Certifications granted.

• Production, Sales and distribution agreement in place with Exelint of USA.

• Production and sales commenced in October 2007.

• Low cost products.

• Recent value add acquisitions.

• Vertically integrated medical products company.

Safety Medical Products Limited is a developer and producer of a range of innovative products for the wholesale and retail medical sector.

Since listing in late 2005, SafetyMed has undergone a period of strong growth through a combination of reaching product development milestones, complementary acquisitions and distribution agreements.

Capital Structure
Shares	Total
	73321072
31/12/2008 $0.20 Options	20107150
31/12/2010 $1.00 Options	35394800
Average Daily Volume (3 months)	39276
52-week High/Low	$1.48/$0.11
Share Price 1/11/2007	0.345

Executive Chairman Mr John Darley

Managing Director and CEO Mr John Riemelmoser Non-Executive Director Dr Joseph Nicholas MB BS (UNSW) Chief Financial Officer Mr Tony Mitchell Company Secretary & Legal Counsel Mr Bruce Hocking LLB

Medical Advisory Board Mr Bruce Hocking LLB (Chairman)

Dr John A Cross MBBS FAFOM GDPH Mr Fred Boswell BSc. Dr Paul Russell MB BS

• Company’s primary objective.

• Development completed with initial production and sales commencing in Oct 2007.

• Only technology to utilise retrofitting process on current standard syringes.

• Advantages:

• Low cost, marginally higher than standard syringe;

• Expandable to full range of sizes;

• Easily adaptable and transportable manufacturing system.

==> picture [401 x 181] intentionally omitted <==

• Exel International strategic alliance to provide access to manufacturing facilities and distribution to overseas markets.

• Sleeve and Locking Mechanism is owned with patent pending by SafetyMed.

• TGA and CE Certifications.

• US based medical products Company.

• Distribution network across US, Japan, Germany and UK.

• Strategic alliance to manufacture and distribute SafetyMed’s SecureTouch™ Retractable syringes.

• Committed to sales of 75 million units over initial two years;

• Sales commitment increasing by 10% per year for five years.

• Initial agreement for a period of five years, with an option of two further five year periods, each exercisable at SafetyMed’s discretion.

• International Production to be based in Seoul, South Korea.

SafetyMed will receive a royalty of USD$0.0135 per unit from the Exel JV.

	Year	Indicative JV Forecasts Units Sold Gross Royalty Revenue USD	Gross Royalty Revenue AUD
	2008 2009 2010 2011 2012	25,000,000 $343,750 50,000,000 $687,500 55,000,000 $756,250 60,500,000 $831,875 66,550,000 $915,063	$381,944 $763,889 $840,278 $924,306 $1,016,736

Exchange Rate = AUD$0.90

• Sales in Australia are forecasted to reach 15 million units in 2008, generating revenue in the order of $2.5m at gross margin of approximately 30%.

• Federal Government funded clean needle program first key –

• Australian market opportunity 50m units per annum.

• Capacity of existing assembly equipment is approximately 3 million units per month.

SecureTouch™ Certification

• TGA Certification for the supply and sale of the SecureTouch™Retractable Safety Syringe in Australia.

• The Company received its Australian Conformity Assessment Certification for the manufacturers of Retractable Syringes in Australia.

• Only certified Company to manufacture Retractable Syringes in Australia.

• CE Marking Certification for sales into 27 countries of the European Union granted.

• Successfully demonstrated compliance to ISO 13485:2003, the International Harmonised Quality System Standard for Medical Device Manufactures

• Recognises highest quality standards for production, warehousing, traceability and documentation procedures.

• In September SafetyMed announced a 1 for 10 pro-rata non-renounceable rights issue to raise approximately $1.9 million.

• Issue Price of $0.28

• Attaching 1 for 2 Bonus Option with strike price $1.00 expiring 31/12/2010

• A total of 1,948,833 rights were taken up, raising approximately $545,673, with 40% of existing shareholders participating

• Under subscriptions totalled 5,142,054 shares

• Currently placing shortfall to interested parties, of which approximately 800,000 shares have been placed or committed to:

• Brokerage fee of 5% applicable

• Net proceeds from the Rights Issue used as working capital to finance costs associated with the commencement of full scale production and commercialisation of the Company’s SecureTouch™ syringe.

Product Development Timeline

May 2007 June 2007 Oct 2007 Nov/Dec 2007 Jan 2008 TBC

• Aims to be a world leader in rapidly growing industry:

• Government regulations changed to promote and enforce the use of safety syringes.

• Expected cheapest products on the market:

• Australian Conformity Assessment Certification: Only company certified to manufacture Retractable Syringes in Australia

• ™

• SecureTouch automated assembly plant completed with initial production commenced in Oct 2007 and full production in early 2008.

• Development of other products and assembly systems accelerated due to recent acquisitions.

• Good position to capitalise on growth opportunities.

• Knowledgeable and experienced Board.